Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Teleflex (TFX)

Teleflex Adds Sean M. Salmon, Former Medtronic Cardiovascular President, to Board

Neutral Impact 2 of 5 leadership Written later

Teleflex expanded its board from eight to nine directors and elected Sean M. Salmon to fill the new seat, effective September 8, 2026. Salmon previously led Medtronic's Cardiovascular portfolio, and the company says his appointment supports its governance and strategic priorities.

Key points

  • Board increased from eight to nine directors; Sean M. Salmon elected to fill the new seat on September 8, 2026
  • Salmon, age 61, founded consulting firm Zamboni Holdings, LLC in December 2025 and previously spent 21 years at Medtronic
  • At Medtronic, Salmon was Executive Vice President and President, Cardiovascular, from January 2021 to September 2025
  • Salmon joins the Growth and Operating Committee; he receives standard non-employee director compensation

The filing

CompanyTeleflex (TFX)
Form8-K, current report
Filed with the SECSep 8, 2026, 5:41 PM ET
Accession number0000096943-26-000101

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 08, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.